3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
3
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
37
Lung Neoplasms
20
Carcinoma, Hepatocellular
18
Breast Neoplasms
16
Small Cell Lung Carcinoma
14
Urinary Bladder Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
7
Liver Neoplasms
7
Neoplasm Metastasis
6
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Ovarian Neoplasms
5
Neoplasms
5
Endometrial Neoplasms
5
Carcinoma, Transitional Cell
5
Carcinoma, Renal Cell
5
Carcinoma
5
Biliary Tract Neoplasms
5
Stomach Neoplasms
4
Melanoma
4
Colorectal Neoplasms
4
Cholangiocarcinoma
4
Prostatic Neoplasms
3
Neoplasms by Site
3
Esophageal Neoplasms
3
Carcinoma, Squamous Cell
3
Uterine Cervical Neoplasms
2
Turcot syndrome
2
Thyroid Neoplasms
2
Thoracic Neoplasms
2
Interventions
pembrolizumab
32
Cisplatin
10
Paclitaxel
8
lenvatinib
6
belzutifan
5
Carboplatin
5
Saline Solution
4
Oxaliplatin
4
Fluorouracil
4
Pemetrexed
3
Leucovorin
3
Etoposide
3
Docetaxel
3
olaparib
2
enfortumab vedotin
2
durvalumab
2
Radiotherapy
2
Levoleucovorin
2
Glucose
2
Capecitabine
2
Bevacizumab
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
tislelizumab
1
sacituzumab govitecan
1
liposomal doxorubicin
1
enzalutamide
1
balstilimab
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
durvalumab
×
Clear all
NCT04380636
2026-05-15
MK-7339-012
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
870 enrolled
NCT05298423
2025-08-01
KEYVIBE-006
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
611 enrolled